Payment overview · 2025
General Payments
$479.24
27 reported records · 7 companies
Healthcare provider profile · identity verified
Dylan Grant Smith, MD
Allopathic & Osteopathic Physicians|Family Medicine · SIOUX CITY, IA · NPI 1194217364
Verified facts
What the public records show
CMS Open Payments records show Dylan Grant Smith, MD received $479.24 in general payments during 2025 across 27 reported records.
PFIZER INC. accounted for 42.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $204.09 | 42.6% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $85.47 | 17.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.05 | 15.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $54.09 | 11.3% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.89 | 5.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.65 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.00 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $479.24 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $128.43 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $85.47 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $77.14 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $77.14 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $73.05 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $73.05 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.89 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 112 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 398 | 119 |
| Lisinopril | Lisinopril | 252 | 71 |
| Gabapentin | Gabapentin | 250 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 247 | 76 |
| Simvastatin | Simvastatin | 151 | 44 |
| Omeprazole | Omeprazole | 144 | 46 |
| Metformin Hcl | Metformin Hcl | 139 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 45 |
| Eliquis | Apixaban | 112 | 20 |
| Losartan Potassium | Losartan Potassium | 108 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 37 |
| Montelukast Sodium | Montelukast Sodium | 104 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 39 |
| Atenolol | Atenolol | 100 | 27 |
| Clonazepam | Clonazepam | 99 | 15 |
| Furosemide | Furosemide | 97 | 30 |
| Sertraline Hcl | Sertraline Hcl | 96 | 20 |
| Potassium Chloride | Potassium Chloride | 91 | 25 |
| Tramadol Hcl | Tramadol Hcl | 87 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 18 |
| Metformin Hcl Er | Metformin Hcl | 63 | 27 |
| Warfarin Sodium | Warfarin Sodium | 62 | 15 |
| Ozempic | Semaglutide | 57 | suppressed |
| Ramipril | Ramipril | 57 | 11 |
| Azithromycin | Azithromycin | 55 | 50 |
| Meloxicam | Meloxicam | 52 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 24 |
| Prednisone | Prednisone | 50 | 46 |
| Spironolactone | Spironolactone | 48 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 12 |
| Jardiance | Empagliflozin | 43 | 11 |
| Finasteride | Finasteride | 42 | 12 |
| Allopurinol | Allopurinol | 38 | 14 |
| Cephalexin | Cephalexin | 38 | 29 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 38 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 11 |
| Glimepiride | Glimepiride | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 13 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Carvedilol | Carvedilol | 32 | 12 |
| Famotidine | Famotidine | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 12 |
| Benazepril Hcl | Benazepril Hcl | 31 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | 13 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | 11 |
| Bumetanide | Bumetanide | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 17 |
| Alprazolam | Alprazolam | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Lorazepam | Lorazepam | 24 | 12 |
| Fentanyl | Fentanyl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 11 |
| Calcitriol | Calcitriol | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | 14 |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Felbamate | Felbamate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 11 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $479.24 · 27 records | PFIZER INC. | ABRYSVO, COMIRNATY, ELIQUIS, INSPIRE, JARDIANCE, Kerendia, NURTEC ODT, PREVNAR 20, QULIPTA, UBRELVY, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error